Obstructive Sleep Apnea Pipeline Drugs Report 2025 By Delveinsight Offering Insights Into Clinical Advancements, Treatment Challenges, And Promising Drugs In Development

DelveInsight's "Obstructive Sleep Apnea Pipeline Insight 2025" report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the Obstructive Sleep Apnea pipeline landscape. It covers the Obstructive Sleep Apnea pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obstructive Sleep Apnea pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Obstructive Sleep Apnea Pipeline? Click here to explore the therapies and trials making headlines @ Obstructive Sleep Apnea Pipeline Outlook Report

Key Takeaways from the Obstructive Sleep Apnea Pipeline Report

• On 18 September 2025, Inspire Medical Systems Inc . announced a study is a prospective, single-arm study conducted under a common implant and follow-up protocol. The objective will be to follow fifty-seven (57) adolescents and young adults (10-21 years of age), with Down syndrome, moderate to severe sleep apnea, and post-adenotonsillectomy, for 12 months after undergoing implant of the Inspire Upper Airway Stimulation (UAS) System. The study is being conducted in order to evaluate objective change in cognition and expressive language after implant and therapy with the Inspire UAS System.
• DelveInsight's Obstructive Sleep Apnea Pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for Obstructive Sleep Apnea treatment.
• The leading Obstructive Sleep Apnea Companies such as Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, Desitin Arzneimittel GmbH, Shionogi Apnimed Sleep Science and others.
• Promising Obstructive Sleep Apnea Therapies such as Sulthiame, AD128, Mannitol, AD313, AVE0657, Eszopiclone, BAY2586116, Atomoxetine, BAY2253651, AD504, Atomoxetine, R-oxybutynin and others.

Want to know which companies are leading innovation in Obstructive Sleep Apnea? Dive into the full pipeline insights @ Obstructive Sleep Apnea Clinical Trials Assessment

The Obstructive Sleep Apnea Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Obstructive Sleep Apnea Pipeline Report also highlights the unmet needs with respect to the Obstructive Sleep Apnea.

Obstructive Sleep Apnea Overview

Obstructive sleep apnea (OSA) is a sleep disorder characterized by repeated episodes of partial or complete airway collapse during sleep, leading to oxygen desaturation and frequent awakenings. These interruptions result in fragmented and nonrestorative sleep, often accompanied by loud snoring, observed apneas, and excessive daytime sleepiness. OSA significantly impacts various aspects of health, including cardiovascular function, behavior, overall quality of life, and driving safety. While other forms of sleep-disordered breathing, such as central sleep apnea, upper airway resistance, and obesity hypoventilation, are distinct conditions, they share similar features with OSA and will be addressed separately.

Obstructive Sleep Apnea Emerging Drugs Profile

• AD109: Apnimed

AD109 is an investigational oral therapy, a pill designed to target the underlying neuromuscular dysfunction in people living with mild, moderate, and severe obstructive sleep apnea (OSA). This novel treatment targets the Hypoglossal Motor Nucleus (HMN) to increase signals in the upper airway dilator muscles during sleep to limit or prevent airway collapse. AD109 could be the first pharmacological treatment to improve oxygenation during sleep by directly addressing the underlying neuromuscular cause of upper airway collapse in people with obstructive sleep apnea. It is a first-in-class combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective noradrenaline reuptake inhibitor (NRI). Their combined pharmacological synergy targets the root neuromuscular cause of OSA. The US Food and Drug Administration (FDA) has also granted Fast Track designation to AD109 for the treatment of OSA. Currently, the drug is in Phase III stage of its development for the treatment of Obstructive Sleep Apnea (OSA).

• IHL-42X: Incannex Healthcare Ltd

IHL-42X is designed to treat OSA by targeting its underlying pathophysiology. An oral fixed-dose combination of dronabinol and acetazolamide, IHL-42X is currently advancing through late clinical stages for the treatment of OSA. Designed to act synergistically, IHL-42X uniquely targets two physiological pathways associated with the intermittent hypoxia (IH) and hypercapnia that characterize OSA. In a prior clinical trial, IHL-42X was shown to reduce the Apnea-Hypopnea Index (AHI) in all dosage strengths, with the lowest dose reducing AHI by an average of 51 percent relative to baseline. Currently, the drug is in Phase II/III stage of its development for the treatment of Obstructive Sleep Apnea (OSA).

• Lorundrostat: Mineralys Therapeutics Inc.

Lorundrostat, an investigational drug, is a novel, oral, highly selective, once-daily aldosterone synthase inhibitor. Lorundrostat targets aldosterone-driven hypertension by inhibiting the enzyme that catalyzes the final steps of aldosterone synthesis. The goal is to decrease levels of aldosterone by selectively inhibiting aldosterone synthesis without affecting cortisol synthesis. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours and demonstrated approximately a 70% reduction in plasma aldosterone concentration in hypertensive subjects. Currently, the drug is in Phase II stage of its development for the treatment of Obstructive Sleep Apnea (OSA)

If you're tracking ongoing Obstructive Sleep Apnea Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Obstructive Sleep Apnea Treatment Drugs

The Obstructive Sleep Apnea Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Obstructive Sleep Apnea with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obstructive Sleep Apnea Treatment.
• Obstructive Sleep Apnea Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Obstructive Sleep Apnea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obstructive Sleep Apnea market.

Obstructive Sleep Apnea Companies

Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, Desitin Arzneimittel GmbH, Shionogi Apnimed Sleep Science and others.

Obstructive Sleep Apnea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Obstructive Sleep Apnea Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

From emerging drug candidates to competitive intelligence, the Obstructive Sleep Apnea Pipeline Report covers it all – check it out now @ Obstructive Sleep Apnea Market Drivers and Barriers, and Future Perspectives

Scope of the Obstructive Sleep Apnea Pipeline Report

• Coverage- Global
• Obstructive Sleep Apnea Companies- Apnimed, Incannex Healthcare Ltd, Mineralys Therapeutics Inc., Eli Lilly and Company, Desitin Arzneimittel GmbH, Shionogi Apnimed Sleep Science and others.
• Obstructive Sleep Apnea Therapies- Sulthiame, AD128, Mannitol, AD313, AVE0657, Eszopiclone, BAY2586116, Atomoxetine, BAY2253651, AD504, Atomoxetine, R-oxybutynin and others.
• Obstructive Sleep Apnea Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Obstructive Sleep Apnea Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what's next for the Obstructive Sleep Apnea Treatment landscape in this detailed analysis @ Obstructive Sleep Apnea Emerging Drugs and Major Players

Table of Contents